A Clinical Study Evaluating the Application of La Roche-Posay's New B5 Multi-Effect Soothing and Repairing Cream on Individuals With Facial Atopic Dermatitis

NCT07022288 | Recruiting

• 1 other identifier: C25005013
• Study Type: interventional
• Target: 76
• Locations: 1 country
• Sites: 1

Brief Summary

This study plans to recruit 76 subjects in accordance with the above inclusion and exclusion criteria, with at least 60 subjects completing the study. The study period is 8 weeks, and the subjects need to visit the research center 4 times. After the subjects are enrolled, they will be randomly divided into two groups, including the experimental product group and the control product group. The physiological indicators of the skin were measured by objective instruments and compared with those of ordinary moisturizers without skin microecological regulation components to evaluate the repair promotion effect and improvement of La Roche-Posay's new B5 Multi-Effect Soothing and Repairing Cream on the affected areas of patients with mild atopic dermatitis on the

Conditions

Atopic Dermatitis of Face

Outcome Measures

Primary Outcomes (6)

• Sebum secretion on the skin surface

  Sebum secretion on the skin surface will be measured by Sebumeter® SM 815 by trained technician.

  Baseline, Time point at 2Week, Time point at 4Week, Time point at 8Week.

• TEWL on the skin surface

  TEWL on the skin surface will be measured by Vapometer by trained technician.

  Baseline, Time point immediate,Time point at 2Week, Time point at 4Week, Time point at 8Week.

• Skin hydration on the skin surface

  Skin hydration on the skin surface will be measured by Corneometer® CM 825 by trained technician.

  Baseline, Time point immediate,Time point at 2Week, Time point at 4Week, Time point at 8Week.

• The pH value of the skin surface

  The pH value of the skin surface will be measured by Skin-pH Meter PH 905 by trained technician.

  Baseline, Time point immediate,Time point at 2Week, Time point at 4Week, Time point at 8Week.

• Standardized facial image acquisition by VISIA

  Trained professionals will use the standard light source and polarized light source in Visia 7 to photograph the frontal, left, and right sides of the study participants' faces for facial image acquisition.

  Baseline,Time point at 2Week, Time point at 4Week, Time point at 8Week.

• The safety and tolerability judgment by dermatologists based on the assessment of interviewed symptoms and observed signs

  During the study, dermatologists will assess the facial condition of study participants. At each visit, each participant will be asked: "Are you experiencing any discomfort now?" If the participant answers "yes", the specific type of discomfort (e.g., tightness, stinging, burning, itching, or any other discomfort) should be recorded, along with the intensity and location of the discomfort. Additionally, dermatologists must carefully document the exact location (e.g., left cheek, right cheek, periocular area, etc.) of observed signs (such as erythema, edema, dryness, desquamation, acne, or any other symptoms) during the examination.

  Baseline,Time point at 2Week, Time point at 4Week, Time point at 8Week.

Secondary Outcomes (7)

• The diagnostic criteria for atopic dermatitis evaluated according to Yao's diagnostic criteria

  Baseline, Time point immediate,Time point at 2Week, Time point at 4Week, Time point at 8Week.

• The IGA (Investigator Global Assessment) scoring conducted by the investigator

  Baseline,Time point at 2Week, Time point at 4Week, Time point at 8Week

• The facial Eczema Area and Severity Index (F-EASI) scoring conducted by the investigator

  Baseline,Time point at 2Week, Time point at 4Week, Time point at 8Week

• The clinical scoring for facial erythema

  Baseline,Time point at 2Week, Time point at 4Week, Time point at 8Week

• Study participants perform visual analog scale (VAS) scoring

  Baseline, Time point immediate,Time point at 2Week, Time point at 4Week, Time point at 8Week.

Study Arms (2)

LA ROCHE-POSAY CICAPLAST BALM

EXPERIMENTAL

Products Application and Usage Instruction Mode of application: 0 Day\~8 weeks Frequency: the study participants should apply LA ROCHE-POSAY CICAPLAST BALM to the entire face twice daily (morning and evening), with each application ranging from 0.5 to 0.75 grams.

Other: LA ROCHE-POSAY CICAPLAST BALM, Standard cream

standard cream

ACTIVE COMPARATOR

Products Application and Usage Instruction Mode of application: 0 Day\~8 weeks Frequency: the study participants should apply standard cream to the entire face twice daily (morning and evening), with each application ranging from 0.5 to 0.75 grams.

Other: LA ROCHE-POSAY CICAPLAST BALM, Standard cream

Interventions

LA ROCHE-POSAY CICAPLAST BALM, Standard cream OTHER

After enrollment, the investigator will generate random serial numbers for grouping through simple randomization. LA ROCHE-POSAY CICAPLAST BALM：8 weeks application It is a leave-on product. It should be applied to the face twice a day during the research period. Standard cream:8 weeks application It is a leave-on product. It should be applied to the face twice a day during the research period.

LA ROCHE-POSAY CICAPLAST BALM; standard cream

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \) Chinese males and females aged 18 to 65 years old (including 18 and 65 years old); 2) In good health, without any other chronic diseases or diseases under treatment; 3) Have received atopic dermatitis drug treatments, including but not limited to:
• Topical glucocorticoids (TSC), such as 0.05% fluticasone propionate cream, 0.1% mometasone furoate cream, 0.1% hydrocortisone butyrate cream, 0.1% triamcinolone acetonide cream, 0.25% hydrocortisone cream, 0.05% desonide cream/ointment, etc.;
• Topical calcineurin inhibitors (TCI), such as 1% pimecrolimus cream, 0.03%/0.1% tacrolimus ointment, etc.;
• Oral antihistamines, such as cetirizine hydrochloride tablets, loratadine tablets, ebastine tablets, azelastine hydrochloride tablets, etc.;
• Other topical medications, such as zinc oxide oil (paste), black bean distillate oil ointment, topical phosphodiesterase 4 (PDE-4) inhibitor ointment, physiological sodium chloride solution, and other wet dressing medications, etc.; 4) At the baseline visit (Baseline), as determined by a dermatologist:
• Meeting Yao's diagnostic criteria,
• Atopic dermatitis severity is mild (Investigator Global Assessment, IGA ≤ 2 points);
• The condition is in a stable phase and no longer requires topical drug treatment 5) At the baseline visit (Baseline), trans-epidermal water loss (TEWL) measurement value \> 15g/m²/h 6) Voluntarily participate in the trial, understand and be willing to sign the informed consent form; 7) Willing to follow the study protocol to use the products provided by the study throughout the study period, not use other similar products, keep diaries, and attend regular follow-ups and other trial requirements.

You may not qualify if:

• \) Study participants who plan to become pregnant, are pregnant, are breastfeeding, are within 6 months after childbirth, or are unwilling to take necessary precautions to avoid pregnancy; 2) Study participants with atopic dermatitis in an acute exacerbation phase; 3) Study participants currently participating in other clinical trials or who have participated in other clinical trials within the past 3 months; 4) Study participants who used functional moisturizers containing skin microecology-regulating ingredients within 1 week before enrollment; 5) Study participants who received physical, chemical, or cosmetic surgical treatments within 3 months before enrollment; 6) Study participants with systemic diseases (severe organ damage), malignant tumors, poorly controlled chronic diseases, acute infectious diseases, major surgeries or trauma, psychological or mental disorders, or who require local or systemic use of drugs/treatments affecting atopic dermatitis due to other diseases; 7) Study participants who experience explosive exacerbation of atopic dermatitis lesions after using the treatment regimen; 8) Study participants with other skin diseases (acne, rosacea, eczema, infections, tumors, etc.) at the study site or other skin conditions interfering with evaluation (birthmarks, scars, etc.); 9) Study participants with a habit of scratching or squeezing atopic dermatitis lesions; 10) Study participants with a history of allergy to the products and related ingredients provided in the study; 11) Study participants with poor compliance, known inability to attend visits on time, or unwillingness to follow the study protocol during the study period; 12) Other circumstances where the investigator deems it inappropriate for the participant to join the study.

Sponsors & Collaborators

• ChinaNorm: lead

Study Sites (1)

Shanghai China-norm Quality Technical Service Co., Ltd.

Shanghai, Shanghai Municipality, 200072, China

RECRUITING

Study Officials

• Ping Xu, Master

  Shanghai China-norm Quality Technical Service Co., Ltd.

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Danwei Chen

CONTACT

15623206068; chendanwei@china-norm.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 21, 2025
• First Posted: June 15, 2025
• Study Start: April 20, 2025
• Primary Completion: August 31, 2025
• Study Completion: October 31, 2025
• Last Updated: June 15, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)